Thomas Jefferson University

Jefferson Digital Commons
Department of Pathology, Anatomy, and Cell
Biology Faculty Papers

Department of Pathology, Anatomy, and Cell
Biology

4-18-2022

GM1 ganglioside modifies microglial and neuroinflammatory
responses to α-synuclein
-synuclein in the rat AAV-A53T α-synuclein
-synuclein model
of Parkinson's disease
Jay S Schneider
Garima Singh
Courtney K. Williams
Vikrant Singh

Follow this and additional works at: https://jdc.jefferson.edu/pacbfp
Part of the Medical Anatomy Commons, Medical Cell Biology Commons, and the Medical Pathology
Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Pathology, Anatomy, and Cell Biology Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Molecular and Cellular Neuroscience 120 (2022) 103729

Contents lists available at ScienceDirect

Molecular and Cellular Neuroscience
journal homepage: www.elsevier.com/locate/ymcne

GM1 ganglioside modifies microglial and neuroinflammatory responses to
α-synuclein in the rat AAV-A53T α-synuclein model of Parkinson's disease
Jay S. Schneider *, Garima Singh , Courtney K. Williams , Vikrant Singh
Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA

A R T I C L E I N F O

A B S T R A C T

Keywords:
α-Synuclein
GM1 ganglioside
Microglia
Neuroinflammation
Parkinson's disease

Among the pathological events associated with the dopaminergic neurodegeneration characteristic of Parkinson's
disease (PD) are the accumulation of toxic forms of α-synuclein and microglial activation associated with neu
roinflammation. Although numerous other processes may participate in the pathogenesis of PD, the two factors
mentioned above may play critical roles in the initiation and progression of dopamine neuron degeneration in
PD. In this study, we employed a slowly progressing model of PD using adeno-associated virus-mediated
expression of human A53T α-synuclein into the substantia nigra on one side of the brain and examined the
microglial response in the striatum on the injected side compared to the non-injected (control) side. We further
examined the extent to which administration of the neuroprotective ganglioside GM1 influenced α-synucleininduced glial responses. Changes in a number of microglial morphological measures (i.e., process length, number
of endpoints, fractal dimension, lacunarity, density, and cell perimeter) were indicative of the presence of
activated microglial and an inflammatory response on the injected side of the brain, compared to the control side.
In GM1-treated animals, no significant differences in microglial morphology were observed between the injected
and control striata. Follow-up studies showed that mRNA expression for several inflammation-related genes was
increased on the A53T α-synuclein injected side vs. the non-injected side in saline-treated animals and that such
changes were not observed in GM1-treated animals. These data show that inhibition of microglial activation and
potentially damaging neuroinflammation by GM1 ganglioside administration may be among the many factors
that contribute to the neuroprotective effects of GM1 in this model and possibly in human PD.

1. Introduction
The mechanisms leading to the initiation and perpetuation of sub
stantia nigra (SN) dopamine (DA) neuron degeneration in Parkinson's
disease (PD) are still not completely known. Mitochondrial dysfunction,
oxidative stress, free radical generation, genetic mutations, neuro
chemical imbalances, defects in ganglioside synthesis and catabolism,
reduced neurotrophic support and/or combinations of these as well as a
number of other factors have been proposed as underlying or contrib
uting to the neuropathology of PD (ex., Ferreira and Massano, 2017;
Hadaczek et al., 2015; Ho et al., 1996; Jenner, 1991; Schapira et al.,
1990; Schapira et al., 1998; Schneider, 2021; Tomac et al., 1995).
Additionally, activated microglia and neuroinflammation, may play an
important role in DA neuron degeneration in the PD brain. Human
leukocyte antigen-DR (HLA-DR) positive microglia (McGeer et al., 1988)
have been found in the SN of idiopathic PD patients as well as in patients

with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
parkinsonism, even years after the original toxin exposure (Langston
et al., 1999). Since these early reports, there are now several additional
lines of evidence that support the idea that activation of microglia, with
subsequent production of pro-inflammatory cytokines, such as tumor
necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta),
plays an important role in the progression of PD pathology (Gerhard
et al., 2006; Mogi et al., 1994; Ouchi et al., 2005; Sanchez-Guajardo
et al., 2010; Zhang et al., 2017).
Preclinical studies have examined the potential role of microglia and
inflammation in DA neuron degeneration in toxin-induced models of PD
(Du et al., 2001; Furuya et al., 2004; He et al., 2001; Kurkowska-Jastr
zebska et al., 1999; LaVoie et al., 2004; Wu et al., 2002) and α-synuclein
(α-Syn) may play an important role in this process. Accumulating evi
dence from various studies also suggests a relationship between α-Syn
oligomerization, generation of reactive oxygen species, oxidative stress,
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(2.55 × 1012 GP/ml) was slowly lowered into the brain and 2.0 μl was
injected at a rate of 0.2 μl/min. The needle was slowly withdrawn
following a 5 min wait period after completion of the injection, the skin
wound was closed, post-surgery analgesia (meloxicam 1 mg/kg) was
administered, and the animal was transferred to a recovery cage.
Rats were randomly assigned to receive either daily GM1 ganglioside
(porcine brain derived GM1, 30 mg/kg, i.p., Qilu Pharmaceutical Co.,
Ltd.) injections or similar volume saline injections for 4 weeks, begin
ning 24 h after AAV-A53T-synuclein surgery. The dose of 30 mg/kg was
selected based on the previously observed positive response of this
model to GM1 ganglioside (Schneider et al., 2019).

and neuroinflammation via activation of microglial cells (Rocha et al.,
2018; Wang et al., 2016; Zhang et al., 2007; Zhang et al., 2005).
Accumulation of wild-type and mutated forms of α-synuclein (i.e., A30P,
A53T) lead to elevated microglia-related ROS production (OstrerovaGolts et al., 2000; Rocha et al., 2018; Wang et al., 2016; Zhang et al.,
2007). Accumulation of wild-type α-Syn in a rAAV model showed that
enhanced α-Syn expression not only leads to persistent microglia acti
vation, but that the degree of SN neuropathology induced by α-Syn in
fluences the type of microglial response that occurs (Sanchez-Guajardo
et al., 2010). For example, α-Syn expression at a level that induced
significant SN DA cell death resulted in the chronic induction of CD68expressing macrophagic microglia (Sanchez-Guajardo et al., 2010).
Despite the evidence supporting a role of microglial activation and/or
neuroinflammatory changes in PD pathology, clinical trials using antiinflammatory therapies have not been successful in slowing the pro
gression of PD (Hung and Schwarzschild, 2020).
We recently reported that treatment with the glycosphingolipid GM1
ganglioside was neuroprotective in an AAV A53T α-Syn model in the rat
(Schneider et al., 2019). Treatment with GM1 ganglioside had beneficial
effects on striatal DA levels and behavior, protected SNc DA neurons
from degeneration, and appeared to decrease the amount of aggregated
α-Syn (Schneider et al., 2019). Gangliosides are sialic acid containing
glycosphingolipids of which the major species in brain are a- and b-se
ries gangliosides GM1, GD1a, GD1b, and GT1b. Gangliosides expressed
by neurons and other cell types in brain serve critically important
physiological functions and GM1, a major component of membrane
signaling domains, plays an important role in variety of process that
could be potentially neuroprotective or disease modifying in PD
including, interacting with a variety of proteins that modulate ion
transport, G protein-coupled receptors (GPCRs), immune system reac
tivity, and neuroprotective signaling (Ledeen and Wu, 2015; Schneider,
2021). Considering the previous data showing neuroprotection from
α-Syn toxicity with GM1 administration, potential anti-inflammatory
effects of GM1, and the knowledge that microglia morphology and
function are closely related (Fernandez-Arjona et al., 2017), the present
study was conducted to investigate the extent to which GM1 adminis
tration in the rat AAV a53T α-Syn model could modulate microglial
morphological characteristics and potentially, neuroinflammatory
processes.

2.2. Behavioral testing
Forelimb use was analyzed using the cylinder test, as previously
described (Schneider et al., 2019). Briefly, an animal is placed in a clear
33 cm × 50 cm Plexiglass cylinder located in a dimly lit room in front of
a mirror in order to visualize limb use from all angles. The paw
contralateral to the side of the AAV-A53T-α-synuclein injection was
marked prior to the start of each test session. Forelimb use was assessed
over a 10 min observation period by scoring twenty observations of
weight-bearing paw placements on the cylinder wall with the ipsilateral,
contralateral (relative to the AAV-A53T-α-synuclein-injected side), and
both paws. Percent ipsilateral (ipsi) and contralateral (contra) paw
touches were calculated as [(ipsi + 1/2 both) / total # observations] *
100 and [(contra + 1/2 both) / total # observations] * 100, respectively.
Testing occurred prior to surgery (baseline) and at 2 and 4 weeks of GM1
or saline treatment.
2.3. Western blotting
For immunoblotting studies, animals were deeply anesthetized and
transcardially perfused with cold PBS to remove blood from the brain.
Fresh brains were rapidly removed, sectioned in a chilled rat brain
matrix, and SN tissue from control and α-Syn-injected sides of the brain
was dissected from 1 mm thick brain sections placed on a chilled
dissection plate, and samples were immediately frozen on dry ice for
later analyses. Dissected SN samples were homogenized in cold RIPA
buffer supplemented with protease and phosphatase inhibitor mix (Halt
Protease and Phosphatase Inhibitor Cocktail, Thermo) using a micro
pestle and then were briefly sonicated. Tissue lysates were then incu
bated at 4 ◦ C with gentle rotation for 30 min and centrifuged at 13,000
rpm, 4 ◦ C for 15 min in a refrigerated microcentrifuge. The supernatant
was then removed and aliquoted into fresh tubes and immediately
frozen on dry ice and stored at − 80 ◦ C. An aliquot of the supernatant was
used to determine the protein concentration of the lysate using a Micro
BCA Assay Kit (Thermo) according to the manufacturer's protocol. Prior
to performing western blotting to evaluate the amount of Iba1 in tissue
lysates, the linear range of signal detection and quantitation for Iba1 and
β-Actin (housekeeping control) was determined using control SN tissue
lysates. Next, 17 μg of SN tissue lysate was mixed with LDS sample buffer
(1× final, GenScript) plus β-mercaptoethanol (Sigma-Aldrich), dena
tured at 70 ◦ C for 10 min and resolved on a 4–20% SurePAGE Bis-Tris
precast gel using MES running buffer (GeneScript). Resolved proteins
were transferred to an activated PVDF membrane (0.2 μ PVDF mem
brane, Millipore) using Transfer buffer (GenScript) containing 10%
Methanol (Fisher Scientific) in an XCell II blot module (Invitrogen).
After protein transfer, the membrane blot was cut into strips, according
to the molecular weight of the proteins analyzed, and blocked in 2.5%
Non-Fat Dry Milk solution (Cell Signaling) in TBS containing 0.05%
Tween-20 (TBS-T). Blots were incubated overnight with anti-Iba1 anti
body (Abcam, Cat# ab178846, RRID: AB_2636859, 1:3000 dilution) or
anti β-Actin antibody (Proteintech, Cat# 66009-1, RRID: AB_2687938,
1:5000 dilution) at 4 ◦ C with gentle shaking. After washing with TBS-T,
blots were incubated with HRP-labeled anti-rabbit or anti-mouse sec
ondary antibodies (Cell Signaling Technology, Cat# 7074, RRID:

2. Materials and methods
2.1. Animals and vector delivery
The vector used in this study (GeneDetect Ltd., Auckland, New
Zealand) has been described in detail previously (Koprich et al., 2011;
Schneider et al., 2019). Briefly, a chimeric adeno-associated vector
(AAV) of a 1/2 serotype (capsid expresses AAV1 and AAV2 serotype
proteins in a 1:1 ratio) with human A53T α-Syn expression driven by a
chicken beta actin (CBA) promoter hybridized with the cytomegalovirus
(CMV) immediate early enhancer sequence was used. A woodchuck
post-transcriptional regulatory element (WPRE) and a bovine growth
hormone polyadenylation sequence (bGH-polyA) were also incorpo
rated to further enhance transcription following transduction.
All animal procedures were approved by the Thomas Jefferson
University Institutional Animal Care and Use Committee and conducted
in accordance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals. Adult male Sprague-Dawley rats (280 to
300 g, Envigo), were housed three to a cage with ad libitum access to
food and water during a 12-hour light/dark cycle. All surgeries were
performed under general isoflurane anesthesia. Once fully anesthetized,
animals were placed in a Kopf stereotaxic frame with the incisor bar set
to achieve a flat skull position. A small incision was made along the
midline of the scalp and a small hole was drilled over the SN (co
ordinates AP: − 5.3, L: 2.2, D: 7.5 below skull) on one side and a 36 gauge
needle attached to a Hamilton syringe loaded with AAV-A53T-synuclein
2
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AB_2099233; Cat# 7076, RRID: AB_330924, 1:10,000 dilution each) for
1 h at RT with gentle shaking. The blots were then washed in TBS-T and
developed using Immobilon ECL Ultra (Millipore) for anti-Iba1 blots and
Immobilon Western Chemiluminescent Substrate (Millipore) for antiβ-Actin blots. The chemiluminiscence signal was imaged using a Fluo
rChem M system (ProteinSimple) and the images were exported to
Image Studio Lite (Version 5.2, LI-COR) software for densitometric
analysis of signal bands. The Iba1 signal was normalized to the β-Actin
signal for each sample and normalized Iba1 signal from the α-Syn
injected side was expressed as a percentage of the signal from the noninjected side.

rectangle tool was used to create a region of interest (ROI) large enough
to capture an entire microglial cell image consistently for each cell to be
analyzed from previously collected binary skeletonized images. The
binary images of microglia randomly selected for fractal analysis were
converted to an outline using the Binary/Outline tool and Fractal
Analysis/FracLac was opened from the plugin toolbar. Once opened, box
counting (BC) was selected from the FracLac menu (grid design Num G
set to 4), convex hull and bounding circle panel was selected and options
boxes metrics, bounding circles, and convex hull were selected. Each
image was then scanned by selecting the Scan button to run a boxcounting scan on the selected image (Young and Morrison, 2018).
Density, span ratio, perimeter, and circularity data were extracted from
the Hull and Circle Results file; fractal dimension and lacunarity data
were extracted from the Box Count Summary Results file (FernandezArjona et al., 2017; Young and Morrison, 2018).

2.4. Immunohistochemistry and microglial analyses
Animals were deeply anesthetized and transcardially perfused with
cold PBS followed by cold 4% paraformaldehyde in PBS. Fixed tissue
blocks were immersed in 30% sucrose for cryoprotection and sectioned
frozen on a sliding microtome. Striatal tissue was sectioned (30 μm
section thickness) and free-floating sections were processed for immu
nohistochemistry. Endogenous peroxidase activity was quenched using
3% hydrogen peroxide in PBS containing 0.1% Tween-20 (PBS/T) fol
lowed by blocking in PBS/T containing 10% normal goat serum and 2%
BSA. Sections were then incubated overnight in Iba1 (Ionized calcium
Binding Adapter molecule 1) primary antibody (rabbit anti-Iba1,
1:5000, EnCor Biotechnology, Inc., Cat# RPCA-IBA1, RRID:
AB_2722747), followed by incubations in biotinylated secondary anti
body (goat-anti-rabbit 1:400, VECTOR Laboratories, Inc., Cat# BA1000-1.5), avidin biotin complex (VECTASTAIN Elite ABC system,
VECTOR Laboratories), and visualization of reaction product using 3,3diaminobenzidine (DAB) (Immpact DAB, VECTOR Laboratories). Sec
tions were then mounted, dehydrated, cleared and coverslipped. Some
sections were processed, using the same methods described above, for
visualization (or absence) of α-Syn using a mouse anti-α-Syn primary
antibody (clone 211; 1:2000, Millipore, Cat# 36-008) and biotinylated
goat-anti-mouse secondary (1:2000, VECTOR Laboratories, Inc., Cat#
BA-9200).
Microglial morphological analyses to quantify process lengths and to
obtain the number of process endpoints were performed using Fiji
(ImageJ) software (RRID: SCR_002285), freely downloadable from http
s://imagej.net/Fiji, and the Analyze Skeleton (2D/3D) plugin (Young
and Morrison, 2018). All slides were coded and all analyses were per
formed with the experimenter blinded to animal identification and
treatment group. The skeleton analysis was performed on brightfield
images of distinct microglial cells captured using a Nikon Eclipse Ni
microscope (20× objective) and NIS-Elements software according to
methods described in detail by Young and Morrison (Young and Mor
rison, 2018). Briefly, 8-bit images of randomly selected microglia cells
from control (non-injected hemisphere) and α-Syn injected hemispheres
from up to 4 sections through the striatum per animal were collected and
converted to skeletonized images by applying an FFT Bandpass Filter to
remove noise, converting images to grayscale, adjusting brightness/
contrast to optimize visualization of microglia processes, applying an
Unsharp Mask filter to further increase contrast, performing a despeckle
step to reduce noise, converting the image to binary and further
reducing noise by applying additional despeckle and Remove Outliers
steps. The optimized binary image was saved and then skeletonized and
analyzed using the Analyze Skeleton plugin with the Branch Information
box checked (Young and Morrison, 2018). Results and branch infor
mation were copied and trimmed (Young and Morrison, 2018) and the
total number of endpoints collected from each microglia image were
calculated along with the summed length of all branches collected from
each microglia image.
Next, fractal analysis of microglia was run using the FracLac plugin,
FracLac for ImageJ (available at the ImageJ website, National Institutes
of Health) according to methods described in detail elsewhere (Fer
nandez-Arjona et al., 2017; Young and Morrison, 2018). Briefly, the

2.5. mRNA expression of neuroinflammatory-related genes
The following genes were chosen for analysis, based on their pur
ported roles in various neuroinflammatory processes: interleukin 1 beta
(IL-1β), interleukin 6 (IL-6), tumor necrosis factor alpha (TNFα), inter
leukin 10 (IL-10), orphan nuclear receptor Nurr1, NLR family pyrin
domain containing 3 (NLRP3) inflammasome; Cathepsin D (CTSD), ni
tric oxide synthase 2 (NOS2), and prostaglandin-endoperoxide synthase
2 (PTGS2). These particular genes have been associated with the
neurodegenerative process in PD, the response to α-Syn toxicity,
microglial inflammatory responses, anti-inflammatory tissue responses,
and/or neuroprotection (Su et al., 2008; Rocha et al., 2018; Chung et al.,
2009; Lobo-Silva et al., 2016; Gordon et al., 2018).
RNA was extracted from fresh frozen SN samples using Zymo
Directzol RNA miniprep Plus. cDNA was prepared using Qiagen Omni
script RT and qPCR was carried out using SYBR Green and commercially
sourced primers from Qiagen against genes described above: IL-1β
(Catalog No. PPR06480B-200), IL-6 (Catalog No. PPR06483B-200), IL10 (Catalog No. PPR06479A-200), Nurr1 (Catalog No. PPR52704F-200),
NLRP3 (Catalog No. PPR56639A-200), CTSD (Catalog No. PPR45222A200), NOS2 (Catalog No. PPR44835A-200), PTGS2 (Catalog No.
PPR49747F-200) on a Roche LightCycler 480 II. To confirm specificity
of amplification the products were subjected to a melting curve analysis
at the end of the final annealing period. The ΔΔCt method was used to
calculate mRNA expression change relative to GAPDH (housekeeping
gene) expression.
2.6. Statistical analyses
All statistics were performed using GraphPad Prism software (v9).
Microglial morphological parameters obtained from cells on the control
and α-Syn-injected sides of the brain in saline control and GM1-treated
animals were compared using two-way analysis of variance followed by
post hoc comparisons using Tukey's multiple comparisons test. Immu
noblotting data and gene expression data were compared by one-way
analysis of variance, also followed by post hoc pair-wise comparisons
using Bonferroni's multiple comparison test. Cylinder test data were
compared using paired t-tests. All analyses were two-sided and statistical
significance was set at P < 0.05.
3. Results
3.1. Alpha-synuclein and GM1 effects on motor behavior
The cylinder test was used to assess spontaneous forelimb use in
AAV-A53T α-Syn-transduced animals. Animals that received AAV-A53T
α-Syn followed by administration of saline or GM1 daily for 2 weeks all
developed a significant asymmetry in paw use with preference for
making contact with the cylinder with ipsilateral forepaw relative to the
side of virus injection (mean ± SEM: baseline/saline: 51.0 ± 2.5%; 2
3
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weeks/saline: 63.8 ± 2.9%, baseline/GM1: 48.0 ± 2.4%; 2 weeks/GM1:
71.0 ± 3.4). There was no significant difference between the saline and
GM1-treated animals in percent of ipsilateral paw use at 2 weeks
(Fig. 1A). At the 4 week point, animals receiving daily saline injections
had increased ipsilateral paw usage compared to 2 weeks whereas ani
mals receiving daily GM1 injections had a decrease in ipsilateral paw
usage compared with 2 weeks and the difference between percent of
ipsilateral paw use between saline and GM1-treated animals was sig
nificant at the 4 week time point (mean ± SEM: baseline/saline: 51.0 ±
2.5%; 4 weeks/saline: 77.0 ± 5.1%, baseline/GM1: 48.0 ± 2.4%; 4
weeks/GM1: 65.0 ± 2.9; Fig. 1B).

were not significant at the 2 week time point, analyses of effects of α-Syn
and potentially modulatory effects of GM1 on microglia morphology
were assessed only at the 4 week time point, when significant behavioral
effects and effects on Iba1 levels in GM1-treated animals were observed.
The α-Syn accumulation in the striatum on the injected side, and absence
on the non-injected side, was confirmed in all animals (Fig. 3).
In the normal, healthy condition, microglia are mostly characterized
by a ramified morphology whereas after injury or in the case of neuro
inflammation, microglia are characterized as having shorter, thicker
processes (Fernandez-Arjona et al., 2017). The number of process end
points (an indication of the extent of process ramification) (Young and
Morrison, 2018) were quantified from photomicrographs of Iba1-stained
microglia in the striatum (control side and α-Syn injected side) of α-Syn/
saline and α-Syn/GM1-treated animals. Following 4 weeks of saline
administration after AAV A53T α-Syn injection into the SN, there was a
significant main effect of α-Syn (F(1, 116) = 30.03, P < 0.0001), a sig
nificant main effect of treatment (F(1, 116) = 13.64, P = 0.0003), and a
significant interaction effect (F(1, 116) = 4.82, P = 0.0303), with a
decrease in the number of endpoints per microglial cell in the striatum
on the α-Syn-injected side of the brain (mean 46.8 ± 3.3) compared to
the control side (mean 76.3 ± 4.5; control side/saline vs. α-Syn side/
saline P < 0.0001). In comparison, there was no significant difference in
the number of endpoints per microglial cell in the striatum on the α-Syninjected side compared to the control side in animals that received 4
weeks of GM1 administration (Fig. 4A). Process length/cell, an addi
tional measure of microglial process ramification was also assessed.
Similar to what was observed for process endpoints, there was a sig
nificant main effect of α-Syn (F(1, 116) = 31.10, P < 0.0001), a significant
main effect of treatment (F(1, 116) = 28.04, P < 0.0001), and a significant
interaction effect (F(1, 116) = 4.37, P = 0.0388), with a decrease in

3.2. Alpha-synuclein and GM1 effects on Iba1 protein levels
Iba1 expression was assessed in the SN lysates 2 weeks and 4 weeks
after unilateral AAV-A53T α-Syn injection and was expressed as a
percent of the expression on the control side of the brain for each animal
(Fig. 2). At 2 weeks, Iba1 expression on the injected side was 163.2 ±
16.1% of that measured on the control, non-injected side in salinetreated animals. The level of expression of Iba1 was similar in animals
that received 2 weeks of GM1 administration (149.6 ± 9.1% on the
injected side relative to the control side). At 4 weeks post AAV-A53T
α-Syn injection, Iba1 expression on the injected side was 178.7 ±
31.0% of that on the non-injected side in saline-treated animals but only
118.7 ± 13.8% on the injected side vs. the non-injected side in GM1treated animals (P < 0.05).
3.3. Alpha-synuclein and GM1 effects on microglial morphology
As effects of GM1 administration on Iba1 protein levels in the SN

Fig. 1. Effect of GM1 on spontaneous forelimb use. (A) At 2 weeks following AAV-A53T α-synuclein injection, saline-treated animals (N = 5) favored the use of the
limb ipsilateral to the injection and this response was also observed in GM1-treated animals (N = 5). There was no significant difference between percent of ipsi
lateral paw use between saline and GM1-treated animals at 2 weeks. (B) At 4 weeks, use of the limb ipsilateral to the injection was favored to a greater extent than it
was at 2 weeks in saline-treated animals (N = 5), but with continued GM1 use, this response was reduced at 4 weeks, resulting in a significant difference between
ipsilateral paw use in saline and GM1-treated animals (N = 5). *P < 0.05 vs. baseline; *P < 0.05 4 week saline vs. 4 week GM1; **P < 0.01 vs. baseline.
4
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Fig. 2. GM1 treatment significantly affected
Iba1 levels in the substantia nigra (SN) at 4
weeks but not at 2 weeks after AAV-A53T injec
tion into the SN. (A) Western blot results (mean
± SEM) are presented as Iba1 expression on the
side of α-synuclein injection as a percent of the
expression level on the contralateral (control,
non-injected) side. There was a significant dif
ference in Iba1 expression between animals that
received 4 weeks of saline injections and those
that received 4 weeks of GM1 injections, with a
decrease in Iba1 expression in GM1-treated ani
mals (N = 5/group, *P < 0.05). (B) Representa
tive Western blots from 2 week and 4 week
animals showing a minimal response to GM1 on
Iba1 expression at 2 weeks and a significant
decrease in Iba1 expression in the SN after 4
weeks of GM1 treatment. Data are shown for SNL (side of AAV-A53T injection) and SN-R (con
trol, non-injected side) from the same animal
following 2 or 4 weeks of GM1 or saline (Sal)
administration. Beta-actin was used as loading

control.

Left

Right

Fig. 3. Immunohistochemical staining of α-synuclein on the side injected with AAV-A53T α-synuclein (left), and the absence of staining on the uninjected control
side (right), four weeks post surgery.

process lengths per microglial cell in the striatum on the α-Syn-injected
side of the brain compared to the control side (control side/saline (mean
513.2 ± 27.3 μm vs. α-Syn side/saline (mean 329.1 ± 22.3 μm, P <
0.0001). In comparison, there was no statistically significant difference
in process lengths of microglial cells on the α-Syn-injected side (mean
506.5 ± 23.6 μm) compared to the control side (mean 590.2 ± 22.5) in
animals that received 4 weeks of GM1 administration (Fig. 4B).
Additional morphological parameters were analyzed to try to gain
additional insight to the effects of both α-Syn and GM1 administration
on microglial responses. There were distinct differences in morpholog
ical profiles of microglia on the α-Syn-injected side in the striatum in
saline control (Fig. 5) compared to GM1-treated animals (Fig. 6). An
increase in density is taken to show the tendency of microglial cells to
become more compact in response to an injury signal (Fernandez-Arjona
et al., 2017). When density was analyzed, there was a significant main
effect of α-Syn (F(1, 56) = 4.37, P = 0.0413) with a significant increase in
this parameter on the α-Syn-injected side (mean 0.035 ± 0.001)
compared to the control side (mean 0.041 ± 0.002) in saline-treated
animals (P = 0.0049) (Fig. 7A). In comparison, there was no statisti
cally significant difference between the density measures on the control
and α-Syn-injected sides in the GM1-treated animals (Fig. 7A). The in
crease in density of microglial cells on the α-Syn-injected side in the
saline control animals indicates the tendency for these cells to become

more compact due to increased α-Syn expression, a microglial response
not seen in the GM1-treated animals.
Fractal dimension, which can identify microglial forms ranging from
rounded to complex branched (Fernandez-Arjona et al., 2017) was
measured and showed a significant effect of α-Syn (F(1, 56) = 19.46, P <
0.0001), a significant effect of treatment (F(1, 56) = 6.46, P = 0.0138)
and a significant interaction effect (F(1, 56) = 10.63, P < 0.0001). There
was a significant decrease in the fractal dimension measure on the
α-Syn-injected side (mean 1.29 ± 0.01) compared to the control side
(mean 1.39 ± 0.01) in saline-treated animals (P < 0.0001) (Fig. 7B). In
comparison, there was no statistically significant difference between the
fractal dimension measures on the control (mean 1.38 ± 0.01) and
α-Syn-injected sides (mean 1.37 ± 0.01) in the GM1-treated animals
(Fig. 7B). The reduction in fractal dimension on the α-Syn-injected side
in the saline control animals indicates a lesser degree of pattern (branch)
complexity of microglial cells that was not observed on the α-Syninjected side in the GM1-treated animals.
Cell circularity (the value of a circle is 1, the value of a linear polygon
is 0) was measured and there was no significant effect of α-Syn (F(1, 56) =
1.633, P = 0.2065) and no significant treatment effect was detected on
this parameter (F(1, 56) = 3.057, P = 0.0859). There were no significant
differences in this parameter on control versus α-Syn-injected sides of
the brain in saline-treated animals nor in the GM1-treated animals
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Fig. 4. Microglial cell ramifications are altered by α-synuclein toxicity and further modified by GM1 administration. At 4 weeks after AAV-A53T injection in to the
SN, microglial activation in the striatum on the injected side (aSyn side) coincided with a significant decrease in cell ramifications, resulting in a significant decrease
in process length per cell (A) and number of endpoints per cell (B), in comparison to the same measure taken from microglia from the non-α-synuclein injected side of
the brain (Control side). GM1 treatment, initiated 24 h after AAV-A53T injection in the SN and administered daily for 4 weeks, resulted in no significant differences in
process lengths or number of endpoints in the a-Syn injected side of the brain compared to the same measures from the Control side of the brain. There was a
significant difference in these measures between the aSyn side in saline-treated animals compared to the aSyn side in the GM1-treated animals (N = 5 animals per
treatment group, 6 cells randomly selected from α-Syn and control sides and analyzed in each animal; ****P < 0.0001 Control side-Saline vs. aSyn side-Saline; ****P
< 0.0001 aSyn side-Saline vs. aSyn side + GM1; ***P = 0.0003 a-Syn side-Saline vs. aSyn side + GM1).

(Fig. 7C).
The parameter of lacunarity measures heterogeneity or invariance in
shape. A low lacunarity value implies homogeneity while a high value
implies heterogeneity, with the image containing many differently sized
gaps or lacunae (Fernandez-Arjona et al., 2017). There was a significant
effect of α-Syn (F(1, 56) = 4.099, P = 0.0477) and a significant treatment
effect on this parameter (F(1, 56) = 6.147, P = 0.0162). Pairwise com
parisons showed a decrease on the α-Syn-injected side (mean 0.39 ±
0.01) compared to the control side (mean 0.43 ± 0.01) in saline-treated
animals (P = 0.045) (Fig. 7D). In comparison, there was no statistically
significant difference between the lacunarity measures on the control
(mean 0.44 ± 0.01) and α-Syn-injected sides (mean 0.44 ± 0.02) in the
GM1-treated animals (Fig. 7D). Since a lower lacunarity value indicates
homogeneity, these data suggest that on the α-Syn-injected side in the
saline control animals, but not in the GM1-treated animals, microglia
changed toward a more homogeneous shape.
In FracLac, the convex hull algorithm measures the size and shape of
a binary image. The convex hull span ratio, also known as form factor, is
the ratio of the major to the minor axes of the convex hull. There were no
significant differences in this parameter between control and α-Syninjected sides in either saline-treated or GM1-treated animals (Fig. 7E).
Cell perimeter was measured based on the single outline cell shape
(Fernandez-Arjona et al., 2017). A more compact shape is associated
with a lower cell perimeter measure. There was a significant effect of
α-Syn (F(1, 56) = 13.85, P = 0.0005), a significant treatment effect
(F(1,56) = 14.42, P = 0.0004) and a significant interaction effect (F(1, 56)
= 4.978, P = 0.0297) on this parameter. Pairwise comparisons showed a
significant decrease on the α-Syn-injected side (mean 1575.0 ± 46.5)
compared to the control side (mean 1782.0 ± 31.7) in saline-treated
animals (P = 0.0005) (Fig. 7F). In comparison, there was no

statistically significant difference between the perimeter measures on
the control (mean 1837.0 ± 30.0) and α-Syn-injected sides (mean
1785.0 ± 29.4) in the GM1-treated animals (Fig. 7F).
3.4. Changes in expression of neuroinflammatory-related genes
There was a significant treatment effect in favor of GM1 for IL-6
(F(3,30) = 36.64, P < 0.0001), IL-10 (F(3,30) = 43.29, P < 0.0001), and
CTSD (F(3,30) = 6.036, P = 0.0024) gene expression. Expression of these
genes were significantly increased in the SN (data expressed as fold
change (±SEM) in left (α-Syn-injected side)/right (control side) ratios)
at 4 weeks post surgery in saline-treated animals compared with gene
expression levels in animals that received 4 weeks of GM1 administra
tion (P < 0.0001 for IL-6 and IL-10; P < 0.01 for CTSD) Fig. 8). There was
a significant treatment effect in favor of GM1 on TNFα gene expression
at 2 weeks post surgery (F(3,29) = 3.332, P = 0.0331) compared to salinetreated animas (P < 0.05), but not at 4 weeks (Fig. 8). Likewise, there
was a significant treatment effect in favor of GM1 on NLRP3 gene
expression at 2 weeks post surgery (F(3,30) = 3.173, P = 0.0384)
compared to saline-treated animals (P < 0.05), but not at 4 weeks
(Fig. 8). There were no significant differences in expression IL-1β, Nurr1,
PTGS2, or NOS2 in saline or GM1-treated animals at either 2 weeks or 4
weeks (Supplementary Fig. 1).
4. Discussion
Microglial cells can display a diverse range of morphologies and
microglial form is linked to microglial function (Karperien et al., 2013).
In the normal mature brain, microglia, engaged in essential physiolog
ical processes, display a ramified profile and typically present as having
6
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Fig. 5. Photomicrographs of microglial morphological changes in the striatum 4 weeks after AAV-A53T α-synuclein injection into the SN in a saline-control animal.
Microglial morphology, evidenced by size and form of the soma and length/branches of process in the striatum on the control (non-injected) side (A and B) was
different than observed in the striatum on the injected side of the brain (D and E), showing larger soma and shorter and fewer branches. Corresponding skeleton
images of these cells (C and F) further demonstrate the change in morphology associated with α-synuclein toxicity.

a relatively small sized soma and long, “spider-like” processes (Karper
ien et al., 2013). In response to injury, microglia adopt an unramified
form typically considered to be “activated” or “reactive”, in which the
soma is relatively large and processes are decreased in number and
complexity. These latter types of microglia are associated with expres
sion of pro-inflammatory proteins (Karperien et al., 2013). In the present
study, we quantified microglial morphology in sections from the stria
tum in animals that received AAV-A53T-α-Syn injection into the SN on
one side of the brain. We describe for the first time, using ImageJ (Fiji)
skeleton and fractal analysis (Morrison et al., 2017; Young and Morri
son, 2018), morphological changes in striatal microglia in response to
α-Syn toxicity, consistent with a neuroinflammatory response, and the
attenuation of this glial response by treatment of animals with the
neuroprotective ganglioside GM1.

Evidence suggests that phosphorylation and aggregation of α-Syn are
involved in the neurodegenerative process in PD, and that the response
to α-Syn toxicity involves a variety of cellular processes, including
adverse effects on mitochondrial function and activation of microglia
(Rocha et al., 2018). The microglial response to toxic α-Syn is complex.
For example, activated microglia can engulf extracellular α-Syn and
clear it from the extracellular space (either to remove potentially toxic
α-Syn derived from dead or dying cells or to remove extracellular/exo
somal α-Syn released from intact cells) and the internalization of α-Syn
into microglia involves GM1 ganglioside (Park et al., 2009). Studies
have shown that GM1 on the cell surface mediates internalization of
α-Syn into microglia (Park et al., 2009): depletion of cell surface gan
gliosides by treatment with the glucosylceramide synthase inhibitor DLthreo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
(PDMP)
7
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Fig. 6. Photomicrographs of microglial morphological changes in the striatum 4 weeks after AAV-A53T α-synuclein injection into the SN in a GM1-treated animal.
While differences in microglial morphology, evidenced by size and form of the soma and length/branches of process in the striatum on the control (non-injected) side
(A and B) vs. the injected side (D and E) could still be observed, there was a trend toward normalization of glial morphology in the GM1-treated animals compared to
the saline-control animals in Fig. 4. Corresponding skeleton images of these cells (C and F) show that the differences in microglial morphology between the
α-synuclein-injected (F) and control sides (C) appear minimal.

inhibited internalization of α-Syn into microglia and this effect was
reversed by addition of GM1 (Park et al., 2009). Thus, microglia (and
actions of GM1 directly on microglia) may participate in a process that
that tries to mitigate α-Syn toxicity and propagation of PD-like
neurodegeneration.
Other lines of evidence show early microglial activation in mice
over-expressing wild-type α-Syn (Su et al., 2008) and a dose dependent
activation of microglia in vitro by α-Syn, coincident with increases in
production of proinflammatory molecules (Su et al., 2008). Microglial
activation and levels of proinflammatory cytokines increase prior to
significant levels of α-Syn-mediated neuronal death (Chung et al., 2009;
Su et al., 2009; Zhang et al., 2017), and it has been suggested that toxic
α-Syn and neuroinflammation may potentiate each other, leading to the
degeneration of DAergic neurons (Zhang et al., 2017). SanchezGuajardo et al. further demonstrated the complexity of the microglial
response in an rAAV α-Syn-based model of PD by showing that distinct
activation profiles of microglia, based on expression patterns of CD8 and
MCH II, are related to the degree to which α-Syn expression results in
cell death (Sanchez-Guajardo et al., 2010). Using a model similar to the

one used in our current study, Chung et al. (Chung et al., 2009) reported
a neuroinflammatory response in the striatum, characterized by
increased levels of Iba-1, activated microglia and increased levels of proinflammatory cytokines, including IL-1β, IFN-γ and TNF-α, 8 weeks
following AAV-A53T α-Syn administration into the SN.
The current results extend the information regarding the early
microglial response to α-Syn by quantifying the morphological changes
that occur in striatal microglia consequent to over-expression of A53T
α-Syn in the SN and the extent to which these changes in microglial
morphology can be modified by GM1 ganglioside administration.
Microglial process length per cell and number of endpoints per cell,
measures of extent of microglial ramification (Young and Morrison,
2018), were significantly decreased in striatum and both measures were
normalized in animals that received four weeks of GM1 administration.
Lower fractal dimension and lacunarity indices indicate decreased
branch complexity and decreased heterogeneity, respectively in α-Syn/
saline-treated animals. Increased density and decreased cell perimeter
measures indicated that microglia in these animals had a more compact
shape, consistent with activation, compared with microglia on the
8
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Fig. 7. Changes in morphological parameters
of density, fractal dimension, lacunarity, and
cell perimeter are consistent with microglial
activation in response to α-synuclein (α-Syn)
toxicity and a reversal of this response in ani
mals treated with GM1 ganglioside for 4 weeks.
In saline-treated animals, activation of micro
glia was evidenced by higher density on the
α-Syn side of the brain vs. the control, noninjected side (A), which together with lower
cell perimeter (F), implies a more compact
shape. These parameters were not significantly
different on the control and α-Syn sides in
GM1-treated animals. Activation of microglia
in saline-treated animals was also implied by
the lower fractal dimension (B) and lower
lacunarity (D) on the α-Syn vs. control sides of
the brain, indicating decreased branch
complexity and heterogeneity, respectively.
These parameters were not significantly
different on the control and α-Syn sides in
GM1-treated animals. (*P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001, for the indi
cated comparisons. Data are presented as box
and whisker graphs (Min to Max) from N = 5
animals per treatment group (saline, GM1) and
N = 3 randomly selected cells from each side of
the striatum from each animal).
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Fig.
8. Upregulation
of
expression
of
neuroinflammation-related genes in response to
α-synuclein overexpression in saline treated ani
mals but not in GM1-treated animals. Expression
of interleukin-6 (IL-6), cathepsin D (CTSD), and
interleukin-10 (IL-10) were significantly upre
gulated at four weeks after AAV-A53T α-synu
clein injection into the SN on the left side
(compared with expression on the right, control
side) in saline-treated animals but not in GM1treated animals. Expression of tumor necrosis
factor alpha (TNFα) and NLR family pyrin
domain containing 3 (NLRP3) inflammasome
were significantly increased in saline-treated
animals but not in GM1-treated animals at two
weeks post surgery and while similar trends were
observed at 4 weeks, these comparisons were not
statistically significant. Data are presented as
mean fold change (±SEM) in left/right ratios
from N = 8 (2 week saline and 4 week saline)
and N = 9 (2 week GM1 and 4 week GM1). *P <
0.05, **P < 0.01, ****P < 0.0001, for the indi
cated comparisons.
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control side of the brain. All of these measures indicative of microglial
activation and neuroinflammation were reversed or normalized in ani
mals treated with GM1 ganglioside. These findings are consistent with a
recent report that gangliosides, and in particular GM1, plays an
important role in modulating microglial functions and responses to proinflammatory signals and exerts an anti-inflammatory effect (Galle
guillos et al., 2022).
Our results using the AAV-A53T-α-Syn model also showed that α-Syn
overexpression results in both microglial activation and upregulation of
pro-inflammatory molecules, consistent with what has been described
by others (Chung et al., 2009; Su et al., 2009; Su et al., 2008). Impor
tantly, we show here that treatment with GM1 ganglioside can at least
partially counteract these adverse responses to potentially toxic α-Syn
accumulation. We found that IL-6, IL-10, CTSD, TNFα, and NLRP3 gene
expression was significantly increased in the α-Syn-injected SN
compared to the control, non-injected SN and that expression was
normalized in GM1-treated animals. There is evidence for α-Syn-medi
ated activation of the NLRP3 inflammasome in the SN in PD as well in
animal PD models, contributing to pro-inflammatory responses and
DAergic neuron degeneration (Gordon et al., 2018). Incubation with
α-Syn produced significant TNFα release from microglia in vitro and
injection of α-Syn into the SN led to upregulation of gene expression of
pro-inflammatory cytokines IL-1β, IL-6 and TNFα by 24 h after injection
(Couch et al., 2011). We have likewise observed an upregulation of gene
expression of IL-6 and TNFα in the SN four weeks after AAV-A53T-α-Syn
injection and this was not seen in GM1-treated animals. Recently Gal
leguillos et al. (2022) reported that GM1 ganglioside administration
decreased inflammatory microglial responses in vivo and in vitro, with
GM1 inhibiting lipopolysaccharide (LPS)-induced IL-1β and TNFα gene
upregulation and decreasing IL-1β, IL-6 and TNFα cytokine levels. Pro
duction of IL-10, an anti-inflammatory cytokine, is an important
mechanism to counteract damage driven by excessive inflammation
(Lobo-Silva et al., 2016), however, the action of IL-10 may vary in
different disease states. In Alzheimer's disease models for example, IL-10
had a detrimental effect on amyloid accumulation and it has been sug
gested that inhibiting the actions of key anti-inflammatory cytokines,
such as IL-10, may allow the brain to return to a physiologically
balanced state with a potentially therapeutic effect (Lobo-Silva et al.,
2016; Guillot-Sestier et al., 2015). IL-10 signaling also upregulated
microgliosis, enhanced neurodegeneration, and decreased survival in
A53T α-Syn transgenic mice (Cockey et al., 2021). In the present study,
we found a significant upregulation of 1L-10 gene expression in AAVA53T-α-Syn/saline treated animals but not in AAV-A53T-α-Syn/GM1treated animals. The ability of GM1 administration to counter a poten
tially detrimental IL-10 response is consistent with the effects of GM1 on
microglial morphology and neuroprotection in this model. The lack of
change observed in gene expression of other inflammatory-related genes
(i.e., IL-1β, Nurr1, PTGS2, or NOS2) in our AAV-A53T-α-Syn/saline
animals was surprising and the reasons for this are not clear at this time,
but may potentially be related to the tissue analyzed (SN versus stria
tum) and/or the time at which the tissues were examined (i.e., 2–4
weeks after AAV-A53T-α-Syn injection). Also, although the current
study did not employ an empty vector control group, we don't believe
that this impacts the results reported. In our previous study of the effects
of GM1 administration in the rat AAV-A53T-synuclein model (Schneider
et al., 2019) we employed an empty vector control and found that the
empty vector produced no pathological response and had no effect on
behavior, striatal DA and metabolite levels, or on SN cell counts. Using
the same AAV-A53T-α-Syn vector that we have used in the prior study
and in the current study, Chung et al. (2009) also showed that AAVA53T-α-Syn vector administration to the SN resulted in an early
appearing microglial activation and neuroinflammatory response in the
striatum and reported no evidence of microglial activation or any in
creases in neuroinflammatory markers in animals that received control
vector injections.
In summary, we previously showed in the AAV-A53T α-Syn model

that GM1 administration was neuroprotective/neurorestorative and that
effects were associated with decreased aggregation of α-Syn and
decreased α-Syn phosphorylation. In addition to decreasing the accu
mulation of toxic forms of α-Syn, the present data show that GM1
treatment also appears to modulate microglial morphology and neuro
inflammatory responses to potentially toxic α-Syn, further contributing
to its neuroprotective/neurorestorative effects. The inhibition of
microglial activation and potentially damaging neuroinflammation by
GM1 ganglioside administration may be among the many factors that
contribute to the neuroprotective/neurorestorative effects of GM1 in the
AAV-A53T α-Syn PD model (Schneider et al., 2019) and possibly in other
PD models (Hadaczek et al., 2015). These mechanisms of action of GM1
may also potentially contribute to a previously reported diseasemodifying effect of GM1 observed in human PD (Schneider et al., 2013).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.mcn.2022.103729.
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